Search results
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise
MedPage Today· 6 days agoNews, features, and commentary about cancer-related issues
Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge
Chicago Sun-Times· 6 days agoWhen doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, retired medical technician ...
MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman
Morningstar· 3 days agoHagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. The investigation currently focuses on the propriety of MacroGenics’ ...
Macrogenics Stock Drops 77% After Study Deaths
The Wall Street Journal· 6 days agoMacroGenics shares plunged 77.4% on Friday, erasing $773.2 million in market value, after the biotech reported late Thursday that five patients died in a...
Natesto: Side effects and what to do about them
Medical News Today· 2 days agoNatesto (testosterone) is a brand-name nasal spray that’s prescribed to treat low testosterone in certain adults. As with other drugs, Natesto can cause...
FogPharma, Artbio join forces to design a different radiopharma drug
BioPharma Dive via Yahoo Finance· 2 days agoThe biotechs aim to marry FogPharma’s polypeptide science with Artbio’s lead-based...
PDS Biotechnology Corp. (NASDAQ:PDSB) Uses Cancer Immunotherapy to Infiltrate and Disable Tumors...
The Wall Street Transcript· 2 days agoDr. Frank Bedu-Addo has served as president and CEO of PDS Biotechnology...veteran biotech executive...
Profound Medical Annual General Meeting of Shareholders Voting Results
Digital Journal· 19 hours agoTULSA-PRO ® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”). Profound is also commercializing Sonalleve ® , an innovative ...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim...
Morningstar· 7 days agoPresentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 7 days agoRakuten Medical Announces Poster Presentation and Booth Exhibition at ASCO 2024 Annual Meeting PR Newswire SAN DIEGO, May 9, 2024 - Poster will highlight interim evaluation update of photoimmunotherapy based on Alluminox™ platform using ASP-1929
